Do weight-loss jabs threaten the future of nutritionists?

The rise of GLP-1 weight-loss injections has led some to wonder whether dieticians and nutritionists could soon become obsolete. But, says The European’s Nutrition & Wellbeing Correspondent Vanessa Previero, the emerging evidence tells a different story: these drugs may ultimately make professional guidance more essential than ever

Few medical treatments have generated as much excitement in recent years as the new generation of GLP-1 weight-loss injections. Originally developed to treat diabetes, drugs such as semaglutide and tirzepatide have quickly become some of the most talked-about developments in modern obesity care.

For many patients they can dramatically reduce appetite, quiet the persistent “food noise” associated with overeating and support substantial weight loss in a relatively short period of time. In some circles they are being described as a breakthrough that could fundamentally change the way obesity is treated.

The speed of that shift has raised an uncomfortable question within parts of the nutrition profession. If medication can suppress appetite and drive weight loss so effectively, where does that leave traditional dietary support? Some practitioners have even begun to wonder whether the widespread adoption of these drugs could represent an existential challenge to dieticians and nutritionists, whose work has long centred on helping people manage weight through food and lifestyle changes.

Yet emerging evidence suggests a different picture may be taking shape. As these medications become more widely used, the need for structured nutritional guidance may actually grow rather than shrink.

The key question is what happens when the injections stop.

A major review published earlier this year in the BMJ examined exactly this issue. Analysing data from 37 studies, the authors found that stopping weight-management medication is often followed by weight regain, with metabolic improvements achieved during treatment gradually returning towards baseline over time. 

Importantly, the researchers focused not simply on whether weight returned, but how quickly it returned once treatment ended, and how that compared with outcomes after behavioural weight-management programmes. 

The findings were broadly consistent. When medication stops, weight commonly returns — often faster than patients expect. GLP-1 drugs work largely by reducing appetite and increasing feelings of fullness. Once treatment ends, the body’s underlying drivers of hunger and weight regulation can reassert themselves.

This is where nutrition professionals may become more important than ever. Weight-loss medications are not designed to operate in isolation, and professional organisations increasingly emphasise that they should be used alongside nutritional and lifestyle support rather than as a standalone intervention.

The BMJ review suggests that weight regain tends to occur more slowly after behavioural programmes such as structured dietary support than after medication alone. Programmes that involve meal planning, self-monitoring and long-term routines appear to leave people with practical skills that help maintain weight once formal treatment ends.

One reason professional guidance becomes important is that rapid reductions in calorie intake can make balanced nutrition harder to maintain. Ensuring adequate protein, calcium, vitamin D and other micronutrients becomes particularly important, as does incorporating resistance training or physical activity to help protect muscle mass and bone health during weight loss.

Nutrition practitioners are also increasingly involved in helping patients manage the practical effects of these medications. Gastrointestinal symptoms such as nausea or constipation are commonly reported, and dietary strategies can help minimise these effects while ensuring nutritional intake remains adequate.

For many patients, smaller meals, careful macronutrient balance and attention to micronutrient intake become central parts of a sustainable approach to weight management. These adjustments often require individual guidance to ensure that reduced appetite does not lead to unintended nutritional deficiencies.

Beyond diet alone, long-term success also depends on behavioural and lifestyle factors. Sleep, physical activity, stress management and sustainable eating habits all influence weight maintenance. Nutrition professionals increasingly support patients in developing routines that work in everyday life, including ways to maintain the social aspects of eating such as meals with friends or dining out.

There is also a broader reason why careful oversight matters. History is full of treatments that initially looked like simple solutions to complex health problems. Cigarettes, for example, were once marketed as appetite suppressants for weight control — a reminder that apparent health solutions sometimes reveal their limitations only over time.

While GLP-1 medications are supported by robust research and have clear clinical benefits, their long-term metabolic effects are still being studied.

The growing availability of these drugs — particularly through private providers — means that many patients now access treatment without comprehensive nutritional support. While the medications can help reduce appetite and support short-term weight loss, maintaining those outcomes often depends on habits that continue after medication ends.

In that sense, the rise of weight-loss injections may not represent a threat to nutrition professionals after all. If anything, they highlight just how important structured nutritional and lifestyle guidance remains in helping patients translate pharmacological weight loss into long-term health.

Vanessa Previero MSc is a London-based Clinical Nutritionist and registered Associate Nutritionist (AfN) with more than two decades’ experience in metabolic health and sustainable weight management. Holding an MSc in Clinical Nutrition from the University of Aberdeen, she brings both clinical training and lived experience to complex cases, including long-term weight management following hypothalamic obesity. As Nutrition & Wellbeing Correspondent for The European, she writes on evidence-based weight management, GLP-1 medications, metabolic resilience and the realities of achieving sustainable health in modern society.

READ MORE: ‘Do women face diagnostic delays in cancer?‘. Research shows that women often face longer waits for a cancer diagnosis than men. These delays are measured in lives, outcomes and lost opportunities for treatment. Here, our health and science correspondent Dr Mohammad Muneeb Khan examines the evidence, the causes and the urgent need for change, and asks whether bias, barriers and systemic blind spots are costing women their futures. His previous article, Trust Me, I’m a Doctor: Here’s How to Spot Cancer Misinformation Online, explores how misleading content can further harm patients and delay care.

Do you have news to share or expertise to contribute? The European welcomes insights from business leaders and sector specialists. Get in touch with our editorial team to find out more.

_{Main image: Towfiqu barbhuiya/Pexels}